Alterations of Monocyte Function in Patients with Growth Hormone (GH) Deficiency: Effect of Substitutive GH Therapy

Serri, Omar

doi:10.1210/jc.84.1.58

Cited by 56 publications

(74 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the ELISA we used detected only the p70 form of IL-12 and, it is possible, an increase in the p40 subunit, whose production greatly exceeds the p70 one, and is easily detectable with an ELISA method. In contrast to our findings in children, in GHD adults basal serum TNF-a and IL6 levels are higher than in controls and decrease after prolonged GH administration, suggesting a different regulation of cytokine production in adulthood (20).…”

Section: Discussioncontrasting

confidence: 99%

Serum cytokine levels in GH-deficient children during substitutive GH therapy

Pagani¹,

Meazza²,

Travaglino³

et al. 2005

eur j endocrinol

View full text Add to dashboard Cite

Objective: The aim of the present study was to investigate the effect of exogenously administered human GH (hGH) on serum levels of interleukin (IL)-4, IL-6, IL-12 and tumour necrosis factor (TNF)-a in GH-deficient (GHD) children. Design and methods: We evaluated 13 short prepubertal GHD children, aged between 2 and 13 years, and 13 age-matched healthy subjects as controls. Circulating cytokine values were evaluated in basal conditions in all children, and 6 and 24 h following the 1st hGH injection (0.23 mg/kg per week), and then after 3 months of hGH treatment in GHD patients. Serum levels of IL-4, IL-6, IL-12 and TNF-a were measured by commercially available ELISAs. Results: No significant differences were found between controls and GHD children in basal values of serum IL-4, IL-6, IL-12 and TNF-a (P . 0.05 by Mann -Whitney U test). Analysis of cytokine levels during hGH treatment showed significant changes over time in TNF-a and IL-6 levels (P ¼ 0.0014 and P ¼ 0.00 024 respectively), with the more pronounced effect observed at 6 h following the first administration of hGH (i.e. increase in IL-6 (Wilcoxon matched pairs test, P ¼ 0.0015) and TNF-a levels (P ¼ 0.0015)). No significant changes over time were observed in IL-4 and IL-12 serum levels. Conclusions: In vivo release of the pro-inflammatory cytokines IL-6 and TNF-a can be affected by hGH treatment in GHD children, suggesting a direct effect of GH on the immune function.

show abstract

Section: Discussioncontrasting

confidence: 99%

Serum cytokine levels in GH-deficient children during substitutive GH therapy

Pagani¹,

Meazza²,

Travaglino³

et al. 2005

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…In untreated GH-deficient patients, unchanged (15) or increased levels of IL6 and TNFa have been reported (35,36), and subsequent GH replacement therapy decreased rather than increased levels of TNFa and IL6 (36,37). In untreated acromegalic patients, a recent study demonstrated increased levels of TNFa (38), but two other studies showed that in active acromegaly, the secretion of IL6 was normal, despite chronically elevated levels of GH and IGF1 (14,15).…”

Section: Discussionmentioning

confidence: 99%

GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist

Andreassen

Frystyk

Faber

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Introduction: The GH/IGF1 axis may modulate inflammatory processes. However, the relationship seems complicated as both pro-and anti-inflammatory effects have been demonstrated. Methods/design: Twelve healthy volunteers (mean age 36, range 27-49 years) were treated in random order with increasing doses of GH for 3 weeks (first week 0.01 mg/kg per day, second week 0.02 mg/kg per day, and third week 0.03 mg/kg per day) or a GH receptor antagonist (pegvisomant; first week 10 mg/day and last two weeks 15 mg/day), separated by 8 weeks of washout. Circulating levels of the pro-inflammatory cytokines tumor necrosis factor a (TNFa (TNFA)), interleukin 6 (IL6), and IL1b (IL1B) and the acute phase proteins (APPs) C-reactive protein (CRP), haptoglobin, orosomucoid, YKL40 (CHI3L1), and fibrinogen were measured. Conclusions: GH/IGF1 action appears to modulate the initial stage of the inflammatory response as well as downstream processes elucidated by levels of APPs. The data suggest a complicated relationship not allowing any simple conclusions as to whether GH/IGF1 actions have mainly pro-or antiinflammatory effects in vivo.

show abstract

“…Indirect evidence to support this hypothesis comes from adult-onset GH deficiency, which is associated with an adverse cardiovascular risk profile and early atherosclerosis (33,34). GH substitution improves markers of atherogenesis (38,39) and reverses early atherosclerotic changes (40). Furthermore, GH treatment presumably via IGF1 enhances nitric oxide bioavailability and increases circulating endothelial progenitor cells, which are involved in vascular function and repair (41).…”

Section: Discussionmentioning

confidence: 99%

Acromegaly per se does not increase the risk for coronary artery disease

Akutsu

Kreutzer²,

Wasmeier³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Information about the risk and course of coronary artery disease (CAD) in acromegaly is limited. Objective: To evaluate CAD risk in acromegalic patients at diagnosis and after successful treatment during follow-up. Subjects and methods: Twenty-five consecutive patients (age 45.1G10.6 years, 15 women) were studied at the time of diagnosis, and 19 patients were re-evaluated after 4.6G1.1 years. The European Society of Cardiology (ESC) risk score was calculated, and a cardiac computed tomography was performed for detection and quantification (Agatston score (AS)) of coronary artery calcium (CACs). Fifty age-, sex-, and CAD risk-matched subjects and CAC data from the population-based Heinz Nixdorf Recall (HNR) study served as controls. Results: In 21 of the 25 patients, the 10-year risk of developing CAD according to the ESC risk score was low (!10%) and high (O20%) in four patients. The AS was lower than in controls (2.6G7.9 vs 66G182; PZ0.014) and less patients had a positive CAC (ASO0) (20 vs 48%, PZ0.024), which in the acromegalic patients was less than expected from the HNR study. The AS did not correlate with GH excess or disease duration. In 19 acromegalic patients, who were in remission and re-evaluated after 4.6G1.1 years, the ESC risk (PZ0.102) and the AS (PZ0.173) did not change significantly and no symptomatic CAD event occurred. Conclusion: CAD risk in newly diagnosed acromegalic patients was low and remained stable after successful treatment. CAC was lower than in controls suggesting that GH excess per se does not carry an additional CAD risk.

show abstract

Alterations of Monocyte Function in Patients with Growth Hormone (GH) Deficiency: Effect of Substitutive GH Therapy

Cited by 56 publications

References 0 publications

Serum cytokine levels in GH-deficient children during substitutive GH therapy

Serum cytokine levels in GH-deficient children during substitutive GH therapy

GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist

Acromegaly per se does not increase the risk for coronary artery disease

Contact Info

Product

Resources

About